Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07686692 · ClinicalTrials.gov registry record · Phase 4
IV Iron Therapy for Older Adults With Heart Failure With Preserved Ejection Fraction and Iron Deficiency
A Phase 4 study, sponsored by Duke University.
- Not yet
- Registry status
- Phase 4
- Development phase
- 300
- Enrollment target
NCT07686692 is a Phase 4 study that has not yet begun recruiting, run by Duke University. The registered enrollment target is 300 participants.
The verdict
NCT07686692, a Phase 4 study, has not yet begun recruiting, sponsored by Duke University.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 300 participants
- Enrollment target
Study Summary
This randomized, double-blind, placebo-controlled clinical trial evaluates intravenous ferric derisomaltose in older adults with HFpEF and iron deficiency.
Interventions
- DRUG Ferric derisomaltose
- DRUG Placebo (normal saline)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-08 |
| Est. Completion | 2030-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07686692
The ClinicalTrials.gov registry entry for NCT07686692 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ferric derisomaltose is the first listed.
NCT07686692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07686692 about?
NCT07686692 is a clinical study titled "IV Iron Therapy for Older Adults With Heart Failure With Preserved Ejection Fraction and Iron Deficiency". This randomized, double-blind, placebo-controlled clinical trial evaluates intravenous ferric derisomaltose in older adults with HFpEF and iron deficiency.
What is the current status of trial NCT07686692?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 300 participants. The study started on 2026-08. Estimated completion is 2030-08.
What interventions are being tested in trial NCT07686692?
The interventions under investigation include: Ferric derisomaltose (DRUG), Placebo (normal saline) (DRUG).
Who is sponsoring clinical trial NCT07686692?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.